TrovaGene, Inc. (NASDAQ:TROV)’s share price rose 0% on Monday . The stock traded as high as $1.08 and last traded at $0.85. Approximately 5,712,488 shares were traded during trading, an increase of 817% from the average daily volume of 623,038 shares. The stock had previously closed at $0.85.

TROV has been the subject of several research analyst reports. Maxim Group set a $4.00 price target on TrovaGene and gave the company a “buy” rating in a report on Thursday, July 27th. Cantor Fitzgerald restated an “overweight” rating on shares of TrovaGene in a report on Tuesday, August 8th.

The firm’s 50-day moving average is $0.73 and its 200-day moving average is $0.89. The stock’s market capitalization is $33.17 million.

Large investors have recently bought and sold shares of the business. LMR Partners LLP purchased a new stake in TrovaGene during the 2nd quarter worth approximately $151,000. Two Sigma Securities LLC grew its position in shares of TrovaGene by 262.4% in the first quarter. Two Sigma Securities LLC now owns 120,516 shares of the medical research company’s stock valued at $139,000 after purchasing an additional 87,264 shares in the last quarter. Susquehanna International Group LLP grew its position in shares of TrovaGene by 2,781.0% in the second quarter. Susquehanna International Group LLP now owns 138,031 shares of the medical research company’s stock valued at $174,000 after purchasing an additional 133,240 shares in the last quarter. KCG Holdings Inc. grew its position in shares of TrovaGene by 560.1% in the first quarter. KCG Holdings Inc. now owns 210,301 shares of the medical research company’s stock valued at $242,000 after purchasing an additional 178,440 shares in the last quarter. Finally, Goldman Sachs Group Inc. grew its position in shares of TrovaGene by 1,079.5% in the second quarter. Goldman Sachs Group Inc. now owns 278,186 shares of the medical research company’s stock valued at $351,000 after purchasing an additional 254,601 shares in the last quarter. Institutional investors own 8.89% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece of content on another domain, it was copied illegally and republished in violation of United States and international trademark and copyright legislation. The legal version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/10/09/trovagene-inc-trov-stock-price-up-0.html.

TrovaGene Company Profile

Trovagene, Inc (TrovaGene) is a molecular diagnostic company. The Company focuses on the development and commercialization of a molecular diagnostic technology for use in disease detection and monitoring across a range of medical disciplines. Its primary internal focus is to leverage its cell-free molecular diagnostic platform to facilitate improvements in the field of oncology, while its external focus includes entering into license agreements or collaborations to develop its technology in areas, such as infectious disease, transplant medicine and prenatal genetics.

Receive News & Stock Ratings for TrovaGene Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TrovaGene Inc. and related stocks with our FREE daily email newsletter.